|
|
| 7:30 |
Registration and Buffet Breakfast |
| 8:00 |
Welcome and Introductions |
| 8:15 |
Future of Medicine Opening Keynote
|
Session I: New Targets and Strategies
| 9:00 |
Extracellular matrix, inflammation, and the angiogenic response |
| 9:30 |
Stromal endothelial cell regulation of cancer progression |
| 10:00 |
Platelet-mediated pro- and antiangiogenic signaling in cancer and health
Giannoula Klement-Lakka, M.D., Tufts University |
| 10:45 |
Multimedia Presentation: Visualizing angiogenesis |
| 11:00 |
VEGF165(B): endogenous regulator of canonical VEGF pathways
David Bates, Ph.D., University of Bristol (UK) |
| 11:30 |
Chromatin insulator binding factor (CTCF) as a regulator of VEGF |
| 12:00 |
Angiogenesis and immunosuppression
George Coukos, M.D., Ph.D., University of Pennsylvania |
| 1:00 |
Networking Luncheon |
Session II: Angiogenesis Biomarkers
| 2:15 |
Human vascular mapping for angiogenesis target and markers
Wadhi Arap, M.D., Ph.D., University of Texas MD Anderson Cancer Center |
| 2:45 |
Adipose-derived progenitor cells and cancer progression |
| 3:15 |
Pericytes as markers for angiogenesis and antiangiogenesis |
| 4:00 |
Emergence of biomarker correlates for VEGF-directed therapies: pVEGF-A
Gordon Jayson, FRCP, Ph.D, Paterson Institute for Cancer Research |
| 4:30 |
Integrin-based tracer imaging to monitor tumor response to antiangiogenic therapy
Peter Choyke, M.D., National Cancer Institute |
| 5:00 |
VEGF-C and VEGF-D mediators of anti-VEGF resistance in colorectal cancer |
| 6:00 |
Networking Reception |
| 7:30 |
Registration and Buffet Breakfast |
Session III: Trends in Angioprevention
| 8:15 |
Obesity-induced angiogenesis and increased cancer risk
Jian-Wei Gu, M.D., University of Mississippi |
| 8:45 |
Caloric restriction and control of tumor angiogenesis and metastases |
| 9:15 |
Micronutrient attenuation of prostate cancer angiogenesis |
| 10:30 |
Patient Advocacy Lecture
Kendal Seidel, Ovarian Cancer Patient Advocate |
Session IV: Clinical Development
| 10:45 |
Targeting vascular endothelial growth factor receptor in thyroid cancer
|
| 11:15 |
Targeting the vasculature in lung cancer
|
| 11:45 |
Patient Advocacy Lecture
|
| 12:00 |
Luncheon
|
| 1:15 |
Anti-angiogenic therapies and Prostate Cancer
Matthew R. Smith, M.D., Ph.D., Massachusetts General Hospital |
| 1:45 |
Antiangiogenic therapy in adnexal cancer
Robert Burger, M.D., Fox Chase Cancer Center |
| 2:15 |
Targeting angiogenesis in sarcoma
|
| 3:00 |
Novel antiangiogenic therapies in colorectal cancer
|
| 3:30 |
Novel VEGF/MET targeting approaches to metastatic breast cancer
Sara Tolaney, M.D., MPH, Dana Farber Cancer Institute |
| 4:30 |
Future of Medicine Closing Keynote
Why don’t we get more cancer: microenvironment and cancer
Mina Bissell, Ph.D., Lawrence Berkley National Laboratory |
| 5:30 |
Closing Remarks & Close of Conference
|
|
| |
|
| |
REGISTRATION
You will receive an email confirmation
of your registration after payment.
Select from the categories below to register for the conference.
Industry $549
|
Clinical/Academic $249
|
Student $119
|
Patient
|
The registration fee includes
- Access to both days of the conference
- Access to exhibit booth area
- Conference materials
- Breakfast on both days
- Lunch on both days
- Cocktail reception/networking event on Saturday evening, October 6th
|
|
Program Description